Yale University  

Calendar

A-Z Index

Yale-CURE BioHaven Entrepreneurship Seminar Series

The Yale-CURE BioHaven Entrepreneurship Series features presentations designed to showcase regionally developed life science technologies that have progressed along the path to commercialization. Speakers at the BioHaven events represent both the scientific and business side of the enterprises. The programs focus on key success factors of each company, scientific or technological advantage, business model, and lessons learned in starting and developing the business. The series also provides social networking opportunities for scientists/researchers in the Yale/New Haven community.

Click here for more information about CURE (Connecticut United for Research Excellence).

Registration for all BioHaven events is free for the Yale community and employees of CURE member companies.

2014 Events

 

Melinta Therapeutics: The Road from the Lab to New Medicines When: Tuesday, April 29, 2014, 4:00 pm program, 5:00 pm networking/refreshments
Where: The Anlyan Center
Speakers: Thomas A. Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry and Professor of Chemistry, Yale University; Co-Founder of Rib-X Pharmaceuticals, which became Melinta
Mary Szela, CEO, Melinta Therapeutics
Eugene Sun, Executive Vice President, R&D, Melinta Therapeutics
The biotech industry is currently facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also address critical commercial goals that include persuasive data to satisfy the payor. At Melinta Therapeutics, commercial needs — particularly payor needs — play a major voice in its R&D strategy.

Melinta Therapeutics' mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. Its late-stage investigational antibiotic, delafloxacin, is currently in Phase 3 development for acute bacterial skin and skin structure infections. In addition, Melinta's RX-04 research program is yielding new classes of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause serious hospital infections.

DATE TBD:

Plant Genomics and Food Sustainability


Past Seminars:

Is DNA Patentable? The Myriad Decision - Impact on Entrepreneurship In Diagnostics and Customized Medicines When: Tuesday, March 25, 2014, 4:00 pm program, 5:00 pm networking/refreshments
Where: The Anlyan Center
Panelists: Nat Brinn, Principal, Vital Venture Capital, LLC
Paul DaSilva Jardine, PhD, Vice President, Cardiovascular and Metabolic Diseases Research Pfizer Global R&D
Anne Maxwell, PhD, JD, Partner, Cantor Colburn LLC
Jon Soderstrom , PhD, Managing Director Yale Office of Cooperative Research
Anthony D. Sabatelli, PhD, JD (moderator), Partner, Dilworth IP, LLC
In 2013, the Supreme Court, in Association for Molecular Pathology v. Myriad Genetics, unanimously held that naturally occurring DNA is a product of nature and not patentable, but that synthetically-produced complementary DNA (cDNA) is.

This BioHaven seminar has convened a panel of experts from various sectors of the biotech and pharmaceutical industry to discuss the business implications of cases such as Myriad.

 

Crowdfunding: Three Different Models When: Thursday, November 14, 2013, 4:00 pm program, 5:00 pm networking/refreshments
Where: The Grove, 760 Chapel St, New Haven
Panelists: Mona Jhaveri, Ph.D., Beats of Laughter
Elgin Tucker, J.D., BlackStartup
Olivia Pavco-Giaccia, Yale '16, Lab Candy
Rob Bettigole (Moderator), Managing Partner, Elm Street Ventures
Three companies and their leaders share what they have learned so far about Crowdfunding, a collective effort of by individuals who network and pool their money usually via the Internet, to finance a particular project or venture.

 

Funding for Innovation When: Wednesday, November 6, 2013, 4:00 pm program, 5:00 pm networking/refreshments
Where: The Anlyan Center
Speakers: Lisa Kurek, Program Director of SBIR Impact NYC and Managing Partner of BBC Entrepreneurial Training and Consulting Presentation pdf
Merrie London, SBIR Manager at Connecticut Innovations Presentation pdf
Margaret Cartiera, Senior Investment Associate at Connecticut Innovations
Mohan Kocherla, Technical Operations Director, Genomas, Inc.
Michael Weiner, Founder and CSO, AxioMx, Inc.
The event will offer expert advice and insight on how innovators can access Small Business Innovation Research (SBIR) grants and matching funds. Lisa Kurek will share the "Keys to Success" in applying for these grants. Merrie London who will provide an overview of the resources available in Connecticut for SBIR winners. A panel of SBIR awardee will discuss how they successfully navigated the process.

There's a wealth of grant money available to researchers through the government's SBIR program. The program can provide up to $150,000 in Phase I grant money and up to $1,000,000 in Phase II grant money. What's more, through the SBIR Acceleration and Commercialization Program from Connecticut Innovations, awardees can receive matching grants of up to $30,000, allowing researchers to gather additional data, protect intellectual property, conduct market research and more. Qualifying companies may apply for up to two of these CI grants per year. Come learn how you can access these funds and accelerate your technology.

 

Trevi Therapeutics When: Tuesday, October 1, 2013, 4:00 pm program, 5:00 pm networking/refreshments
Where: The Anlyan Center
Speakers: Jennifer Good, President & CEO
Thomas Sciascia, M.D., CMO
Trevi Therapeutics, Inc. is a New Haven-based development company focused on developing nalbuphine ER for chronic pruritus (itch). For its lead indication, the Company is pursuing luremic pruritus, a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. Because of Nalbuphine ER's centrally acting dual mechanism of action, the company believes it can have broad utility in treating chronic pruritus and is actively pursuing a second indiction in dermatology.

 

Today's Bioscience Funding Environment: An Investment Banker's Perspective When: Tuesday, September 24, 2013, 4:00 pm program, 5:00 pm networking/refreshments
Where: The Anlyan Center
Speaker: Tony Gibney, Managing Director, Leerink Swan
Tony Gibney is a Managing Director at Leerink Swann in New York, where he has led the Firm’s East Coast biopharmaceuticals investment banking franchise since joining the the company in 2009. In addition to having primary coverage responsibilities for East Coast biopharma companies, Tony also manages several relationships with larger European-based pharmaceutical companies. Previously Tony led the East Coast biotechnolgoy and branded specialty pharmaceutical effort for the majority of his 10-year tenure at Merrill Lynch.

 

Jackson Laboratory for Genomic Medicine followed by a conversation with UCONN and Yale When: Tuesday, April 30, 2013, 4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: Hope Building, Room 216, 315 Cedar St
Panelists: Edison Liu, M.D., President and CEO, The Jackson Laboratory
Marc Lalande, Ph.D., Professor and Chairman of the Department of Genetics and Developmental Biology, and Associate Dean for Research Planning and Coordination at the University of Connecticut School of Medicine
Haifan Lin, Ph.D., Professor of Cell Biology and of Genetics at Yale University; Director, Yale Stem Cell Center
Susan Froshauer, Ph.D. (Moderator), President and CEO, CURE

The State of Connecticut has made a $291 million dollar bet that Jackson Laboratory for Genomic Medicine (JAX) will help Connecticut assume a position of global leadership in personalized medicine. By combining JAX’s strength in genetic technologies with the clinical and scientific expertise of University of Connecticut and Yale, both the State and the research community are hoping to see accelerated development of medical treatments and tests tailored to patient’s specific genetic make up.

 

Yale Entrepreneurial Institute (YEI)
Three Recent Student-Led Start-Ups in Healthcare
When: Tuesday, February 26, 2013, 4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: The Anlyan Center
Moderator: James G. Boyle, Ph.D., Director, Yale Entrepreneurial Institute
For more than 6 years, The Yale Entrepreneurial Institute has helped Yale students develop entrepreneurial skills by launching businesses. Recently the program expanded to include start ups that involve Yale intellectual property and faculty.

At BioHaven, students, faculty and mentors will share their experiences with YEI using real life examples of how the program has connected students to Connecticut business people -- many of whom has participated as mentors, advisors and investors.

 

C8 Sciences: Cognition Cross-Training for Children and Adults When: Wednesday, January 30, 2013, 4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: The Anlyan Center
Speakers: Bruce E. Wexler, M.D., Professor Emeritus of Psychiatry and Senior Research Scientist, Yale Medical School; Director of the Neurocognitive Research Laboratory, Connecticut Mental Health Center
Ken Coleman, President and Co-Founder

C8 Sciences develops and markets neuroscience-based cognition assessment and development products that have the potential to solve some of the most significant problems affecting children and the aged. C8 is the only company to offer integrated computer and physical exercises - "cognition cross-training." Its products are based on proprietary research developed at Yale University by Dr. Bruce Wexler, and the company was recently awarded a prestigious $3M Director's Office Grant by the National Institutes of Health to study the use of C8Kids for treating ADHD. This grant is reserved for research programs that have the potential for a paradigm change in US healthcare.

 

Transformational US Healthcare Opportunities in the Decade Ahead When: Wednesday, January 23, 2013
4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: The Anlyan Center
Speaker: Richard N. Foster, Ph.D., Senior Faculty Fellow, Yale
School of Management; emeritus director, McKinsey & Company, Inc.; Managing Partner, Millbrook Management Group; Venture Partner, Lux Capital Groupneurial Institute

A senior faculty fellow at Yale School of Management, Richard N. Foster is an emeritus director of McKinsey & Company, Inc. where he was director and senior partner. While at McKinsey he founded several practices including the technology and innovation practice, the healthcare practice and the private equity practice. A best selling author, Dr. Foster's research interests are in the relationships between capital formation, innovation, and regulation. Dr. Foster has written two bestselling books: Innovation: The Attacker's Advantage (1986) and Creative Destruction (2001), as well as several dozen articles in research and popular journals.

 

Innovation and the Future of the Affordable Care Act after Election 2012 When: Tuesday, November 13, 2012, 4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: Kline Geology Laboratory Auditorium, 210 Whitney Ave (Parking Lot 22)
Panelists: Michael Woody, partner in the Washington lobbying firm East End
David Boyer, vice president of the bipartisan lobbying firm BGR Government Affairs
Connecticut Biotechnology Growth Council Members
Paul Pescatello (Moderator), President and CEO, CURE

Biopharma industry and legal experts analyze the recent Supreme Court decision regarding the Affordable Care Act and explain how implementation of the ACA will affect new medicine and medical device R&D and pricing, as well as life sciences innovation generally. Occurring just 10 days after the presidential election, this joint BioHaven / CURE Annual Meeting session will be a great chance to see where we are and whether adjustments need to be made to investment, business and research plans.

 

Today's Investment Landscape for Life Sciences When: Thursday, October 11, 2012, 5:00 pm program, 6:00 pm networking, refreshments and wine bar
Where: Harkness Lounge, 367 Cedar Street, New Haven
Speaker: Mary J. Tanner, Managing Director, Peter J. Solomon Company
A managing director in the Peter J. Solomon investment banking advisory firm, Mary Tanner co-heads with her husband Fred Frank the company's global pharmaceutical and life science practice. Mary has devoted more than 25 years to the global healthcare industry and counts among her many clients and accomplishments: Pfizer in its $60B acquisition of Pharmacia; Amgen in its $16B acquisition of Immunex; Rhone-Poulenc in its acquisition of Rorer; then Rhone-Poulenc Rorer in its acquisition of UK company Fisons; BASF/BASF Pharma, a German company, in its acquisition of UK company Boots Pharmaceuticals. She serves on the Dean's Council of the Yale Medical School and the Yale University Council on Technology Transfer.

 

Chondrogenics,

Inc.

When: Thursday, April 26, 2012, 4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: The Anlyan Center
Speakers: Caroline Dealy, Ph.D., Scientific Founder and Associate Professor, Center for Regenerative Medicine and Skeletal Development, UConn Health Center
James Heym, Ph.D., Senior Director of Life Science Ventures, UConn R&D Corp.
  Archive: Video
Chondrogenics, Inc. is developing stem cell therapy for the treatment of osteoarthritis and the repair of damaged cartilage associated with diseased and damaged joints. Dr. Dealy and colleagues have developed a novel process for producing substantially homogeneous populations of chondrogenic cells and earlier progenitor cells from stem cells, including induced pluripotent stem cells.

 

Soft Tissue

Regeneration, Inc.


STR
When: Thursday, March 29, 2012, 4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: The Anlyan Center
Speaker:

Archive:
Joseph Reilly, President and CEO

Video
Soft Tissue Regeneration, Inc. (STR) is an early-stage orthopaedic device company developing a breakthrough, tissue engineering platform used to regrow ligaments and tendons. STR’s first product, the L-C Ligament® is a ready to use, biocompatible and biodegradable synthetic scaffold that facilitates re-growth of a patient’s anterior cruciate ligament (ACL) within the knee – providing joint stabilization and ultimately resulting in faster, better healing and greater odds of making a full recovery. The Company’s proprietary and patented technology utilizes and FDA-approved degradable polymer. more »

 

Personalized

Medicine:

How Far Off?


CVG
When: Tuessday, February 28, 2012, 4:30 pm registration, 5:00 pm program, 6:00 pm networking, refreshments and wine bar
Where: Harkness Auditorium (NOTE LOCATION CHANGE)
Panelists: Richard Lifton, M.D., Ph.D., Sterling Professor of Genetics and Professor of Medicine (Nephrology), Yale University; Chair, Department of Genetics
Thomas Lynch, M.D., Director, Smilow Cancer Center at YNHH
Jonathan Rothberg, Ph.D. , Founder, CEO and Chairman, Ion Torrent Systems, Life Technologies
Timothy Shannon, M.D., Partner, Canaan Partners
Paul Pescatello (Moderator), President and CEO, CURE
  Archive: Video
Genomic technologies have opened the door to medicine that takes into account the unique clinical, genetic, genomic and environmental characteristics of individuals. This session will explore the state of personalized medicine today, its application both scientifically and in the clinic and commercial opportunities and challenges in the near and mid-term.

 

Thetis

Pharmaceuticals,

Inc.

When: Wednesday, January 25, 2012, 4:00 pm program, 5:00 pm networking, refreshments and wine bar
Where: The Anlyan Center
Speakers: Gary Mathias, Chief Financial Officer
Frank Sciavolino, Ph.D., Chief Scientific Officer and Co-founder
  Archive: Video
Thetis Pharmaceuticals is a drug development company that is advancing TP101, a novel, first-line therapy for type 2 diabetes. TP101 is a new molecular entity that chemically combines metformin, the standard of care in type 2 diabetes, with the principal component from omega-3 polyunsaturated fatty acids. TP101 uniquely targets both glycemic and lipid control in diabetes patients and, for the first time, offers prospects for addressing the high incidence of cardiovascular complications, a major risk factor in type 2 diabetic and pre-diabetic patients. The company expects to begin clinical studies with TP101 in 2012.

 

Healthcare IT:

Challenges and

Opportunities


CVG
When: Tuesday, November 15, 2011, 4:30 pm registration, 5:00 pm program, 6:00 pm networking, refreshments and wine bar
Where: The Anlyan Center
Panelists: David Jahnes, Managing Partner, Galen Partners
James Staten, Executive VP, Corporate and Financial Services, YNHHS and CFO and Senior VP for Finance, Yale-New Haven Hospital
Matt Walton, CEO, MyCare LLC
Health IT is a booming field. Document management for Electronic Health Records and demands for mobility while ensuring the security of medical records are major concerns for providers. Entrepreneurs are navigating a regulatory environment that is more complex than ever before while racing to implement the connectivity required for Healthcare Information Exchanges. How are providers incorporating clinical decision support into practices? Where are investors putting their money? An all-star panel of a hospitalist, a regulatory expert, an investor and entrepreneur talk about where Health IT is trending.

 

Axerion

 

Therapeutics

When: Wednesday, March 2, 2011, 4:00pm seminar, 5:00pm networking, refreshments and wine bar
Where: The Anlyan Center
Speaker: Sylvia McBrinn President and Chief Executive Officer;
Stephen Strittmatter, M.D. Ph.D.;
Vincent Coates Professor of Neurology, Yale University
Professor of Neurobiology, Yale University
  Archive: Video

 

novatract

When: Wednesday, February 16, 2011, 4:00pm seminar, 5:00pm networking, refreshments and wine bar
Where: The Anlyan Center
Speaker: Eleanor Trandler President and CEO; Kurt Roberts, M.D. Assistant Professor of Surgery, Yale University
  Archive: Video

 

miradx

When: Wednesday, January 19, 2011, 4:00pm seminar, 5:00pm networking, refreshments and wine bar
Where: The Anlyan Center
Speaker: Martin L. Verhoef, President ; Frank Slack, Ph.D. Associate Professor, Department of Molecular, Cellular and Developmental Biology, Yale University
  Archive: Video

 

biodel

When: Thursday, November 18, 2010, 4:00pm seminar, 5:00pm networking, refreshments and wine bar
Where: Yale Epidemiology & Public Health Building (LEPH), 1st Floor, Winslow Auditorium, 60 College Street (corner of South Frontage Road), New Haven (NOTE LOCATION CHANGE)
Speaker: Solomon S. Steiner, Ph.D. Chief Scientific Officer and Co-Founder; Erroll De Souza, Ph.D. President and CEO
  Archive: Video

 

cobalt

When: Wednesday, October 27, 2010, 4:00pm seminar, 5:00pm networking, refreshments and wine bar
Where: Hope Auditorium
Speaker: Seth Feuerstein, M.D., J.D. Cobalt Therapeutics
  Archive: Video

 

Al Mann

When: Thursday, September 16, 2010, 6:00pm seminar, 7:00pm networking, refreshments and wine bar
Where: Hope auditorium, Yale Medical School (300 Cedar Street)
Speaker:

 

Alfred E. Mann has founded and largely funded 17 companies in his career. Nine were acquired at an overall total of almost $8 billion, and two became public companies. He is currently chairman and EO of Mannkind Corporation.
  Archive: Video

 

 

 

 

 

 

 

 

kolltan

When: Wednesday, May 26, 2010
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speaker: Arthur G. Altschul, Jr., Co-Founder and Chairman of the Board; Joseph Schlessinger, Ph.D., Co-Founder, Director and Scientific Advisory Board Chairman and Michael Schmertzler, Chief Executive Officer
  Archive: Video

 

js genetics

When: Wednesday, May 12, 2010
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speaker: Alidad Mireskandari, President & CEO and Jeff Gruen, M.D., Co-founder of JS Genetics, Scientific Advisory Board Chairman
  Archive: Video

 

Amarin

When: Thursday, April 8, 2010
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speaker: Paresh Soni, M.D., PhD, Senior Vice President and Head of Development
  Archive: Video

 

Jonathan Rothberg When: Wednesday, March 31, 2010
Where: 110 Hope Memorial Building, 315 Cedar Street
Speaker: Jonathan Rothberg, Founder of 454 Life Sciences, CuraGen, Clarifi Corporation, The Rothberg Institute of Childhood Diseases, Ion Torrent Systems, Founder and chair, RainDance Technologies

 

Arbor Fuel When: Thursday, February 25, 2010
Where: Yale University, Kline Geology Lab Building, 210 Whitney Ave, New Haven
Speaker: Steven Henck, President & CEO

 

 

Advanced Orthopedic Technologies & CardioPhotonics When: Thursday, January 28, 2010
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speaker: Thomas Wood, President & CEO; John S. Reach, M.Sc., M.D.; Kirk Shelley, M.D., Ph.D.
  Archive: Video

 

helix When: Wednesday, November 18, 2009
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speaker: Joseph Catino, Ph.D.; Peter M. Glazer, M.D., Ph.D.

 

CaraTherapeutics When: Wednesday, October 21, 2009
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speaker: Derek Chalmers, Ph.D., D.Sc, President & CEO

 

 

When: Wednesday, May 6, 2009
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: Michael Sherman, President, and Michael Weiner, Vice President of Molecular Sciences
  Archive: Broadband | Modem
(RealPlayer required)

 

Cell Design When: Wednesday, March 25, 2009
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: John Hambor, Ph.D., Chief Executive Officer, CellDesign and Linda Powers, Co-Founder and Managing Director, Toucan Capital, Inc.
  Archive: Powerpoint
  Archive: Broadband (RealPlayer required)

 

carigentlogo

 

When: Thursday, March 5, 2009
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: Seth Feuerstein MD JD, President; W. Mark Saltzman PhD. Scientific Advisor and Tarek Fahmy PhD. Scientific Advisor
  Archive: Broadband (RealPlayer required)

 

Unexpected Outcomes: Navigating Scientific & Management Land Mines

 

When: Thursday, November 13, 2008
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: Michael Kishbauch, Ph.D., President & CEO, Achillion Pharmaceuticals Inc.; Tom Wood, Founding CEO, Applied Spine Technologies; Ron Lennox, D. Phil., Partner, CHL Medical Parnters
    More info...

 

When: Thursday, October 16, 2008
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: Geoffrey Erickson, Ph.D., President & CEO, Humacyte, Inc.
Laura Niklason, M.D., Ph.D., Founder & CSO, Humacyte, Inc., Associate Professor of Anesthesia & Biomedical Engineering, Yale University
    More info...

 

When: March 19, 2008
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: Colin Foster, President and Chief Executive Office, Optherion
Amanda Hayward, Ph.D., Senior Vice President, Scheer & Company, Inc.
    More info...

When: April 16, 2008
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: Roger Longman, Managing Partner, Windhover Information Inc.(moderator)
William Burkoth, Senior Manager, Pfizer’s Venture Investments Group, Pfi zer Inc.
Richard Flavell, Ph.D., Professor and Chairman of Immunobiology; Professor of Molecular, Cellular & Developmental Biology, Yale University; Investigator, Howard Hughes Medical Institute
Haifan Lin, Ph.D., Professor of Cell Biology; Director, Yale Stem Cell Center
David Scheer, President, Scheer & Company, Inc.
    More info...

When: April 23, 2008
Where: The Anlyan Center auditorium, Yale Medical School (300 Cedar Street)
Speakers: Ben Bronstein, M.D., Co-founder; President/ COO, Vidas Ocular
Bruce Shields, M.D., Marvin L. Sears Professor and Chairman Emeritus, Department of Opthamology and Visual Science, Yale University School of Medicine; Co-Founder; Chief Scientific
and Medical Officer, Vidus Ocular
    More info...

 

When: February 12, 2008
Speakers: Susan Froshauer, Ph.D.
President and CEO, Rib-X
Archive: Broadband | Modem
(RealPlayer required)
    More info...

More information... (pdf)
When: November 13, 2007
Speakers: John P. Marano, Jr., Ph.D., Co-Founder, President & CEO, Vascular Insights LLC
Michael Tal, M.D., Associate Professor of Radiology, Yale School of Medicine; Co-Founder, and Chief Medical Advisor, Vascular Insights LLC
Archive: PowerPoint
Video:
Broadband | Modem
(RealPlayer required)
  More info...

When: October 24, 2007
Speakers: Ronald W. Lennox, D. Phil. Partner, CHL Medical Partners and Interim CEO, BioRelix Pharmaceuticals, Inc.
Ronald Breaker, Ph.D. Henry Ford II Professor in the Department of Molecular, Cellular and Developmental Biology, Yale University; Investigator, Howard Hughes Medical Institute
Video:
Broadband | Modem
(RealPlayer required)
    More info...

When: January 17, 2007
Speakers: Peter Fuller, Ph.D., Chief Operating Officer, CGI Pharmaceuticals, Inc.
Ira Mellman, Ph.D., Yale University Sterling Professor of Cell Biology & Immunology; Founder & Scientific Advisor, CGI Pharmaceuticals, Inc.
Video:
Broadband | Modem
(RealPlayer required)

 

 

 





 

Applied Spine Technologies
Applied Spine Technologies
When: December 13, 2005
Speakers: Tom Wood, Applied Spine
Manohar Panjabi, Yale
Video:
(MPEG®)
(RealPlayer required)

 
Top of page.